Human genetic variation: New challenges and opportunities for doping control

Journal of Sports Sciences

Volumn 30, Issue 11, 2012, Pages 1117-1129

  Schneider, Angela J ^a   Fedoruk, Matthew N ^b   Rupert, Jim L ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b Canadian Centre for Ethics in Sport   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

doping; doping control; Genetics

Indexed keywords

ADRENERGIC RECEPTOR; ERYTHROPOIETIN RECEPTOR; MSTN PROTEIN, HUMAN; MYOSTATIN; TESTOSTERONE;

ATHLETE; ATHLETIC PERFORMANCE; BLOOD; CHIMERA; DOPING; DRUG EFFECT; ETHICS; FEMALE; GENETIC VARIABILITY; GENETICS; GENOTYPING TECHNIQUE; HEMATOCRIT; HUMAN; LEGAL ASPECT; MALE; METHODOLOGY; PHYSIOLOGY; PRIVACY; REVIEW; URINE;

ATHLETES; ATHLETIC PERFORMANCE; CHIMERA; DOPING IN SPORTS; FEMALE; GENETIC VARIATION; GENOTYPING TECHNIQUES; HEMATOCRIT; HUMANS; MALE; MYOSTATIN; PRIVACY; RECEPTORS, ADRENERGIC; RECEPTORS, ERYTHROPOIETIN; TESTOSTERONE;

EID: 84864538307     PISSN: 02640414     EISSN: 1466447X     Source Type: Journal    
DOI: 10.1080/02640414.2012.692480     Document Type: Review

References (73)

1. Amant, F., Dorfling, C.M., de Brabanter, J., Vandewalle, J., Vergote, I.Lindeque, B.G. 2004. A possible role of the cytochrome P450c17alpha gene (CYP17) polymorphism in the pathobiology of uterine leiomyomas from black South African women: A pilot study. Acta Obstetricia et Gynecologica Scandinavica, 83: 234-239.
2. An, X. and Mohandas, N. 2008. Disorders of red cell membrane. British Journal of Haematology, 141: 367-375.
3. Ayotte, C. 2008. Suivi des profils de stéroïdes urinaires dans le contrôle du dopage des sportifs (Follow-up of the urinary steroid profiles in athlete doping control). Revue Francophone des Laboratoires, 401: 39-46.
4. Ayotte, C. 2010. "Detecting the administration of endogenous anabolic androgenic steroids". In Doping in sports, Edited by: Thieme, D. and Hemmersbach, P. 77-98. Berlin: Springer. Handbook of Experimental Physiology #195
5. Baoutina, A., Coldham, T., Bains, G.S. and Emslie, K.R. 2010. Gene doping detection: Evaluation of approach for direct detection of gene transfer using erythropoietin as a model system. Gene Therapy, 17: 1022-1032.
6. BBCNews. 2002. http://news.bbc.co.uk/winterolympics2002/hi/english/other_skiing/ newsid_1839000/1839176.stm
7. Bray, M.S., Hagberg, J.M., Perusse, L., Rankinen, T., Roth, S.M.Wolfarth, B. 2009. The human gene map for performance and health-related fitness phenotypes: The 2006-2007 update. Medicine and Science in Sports and Exercise, 41: 35-73.
8. Brooks, M.A. and Tarini, B.A. 2011. Genetic testing and youth sports. Journal of the American Medical Association, 305: 1033-1034.
9. Castella, V., Morerod, M.L., Robinson, N., Saugy, M. and Mangin, P. 2007. Successful DNA typing of ultrafiltered urines used to detect EPO doping. Forensic Science International: Genetics, 1: 281-282.
10. Chakraborty, A., Murthy, N.S., Chintamani, C., Bhatnagar, D., Mohil, R.S.Sharma, P.C. 2007. CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. Journal of Human Genetics, 52: 159-165.
11. Chen, J.W., Uboh, C.E., Soma, L.R., Li, X., Guan, F.You, Y. 2010. Identification of racehorse and sample contamination by novel 24-plex STR system. Forensic Science International: Genetics, 4: 158-167.
12. Collins, F.S. and Mansoura, M.K. 2001. The Human Genome Project: Revealing the shared inheritance of all humankind. Cancer, 91(suppl. 1): 221-225.
13. Davis, E., Loiacono, R. and Summers, R.J. 2008. The rush to adrenaline: Drugs in sport acting on the beta-adrenergic system. British Journal of Pharmacology, 154: 584-597.
14. de la Chapelle, A., Traskelin, A.L. and Juvonen, E. 1993. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proceedings of the National Academy of Science USA, 90: 4495-4499.
15. Delmore, R.J., Hodgen, J.M. and Johnson, B.J. 2010. Perspectives on the application of zilpaterol hydrochloride in the United States beef industry. Journal of Animal Science, 88: 2825-2828.
16. Duan, Q.L., Gaume, B.R., Hawkins, G.A., Himes, B.E., Bleecker, E.R.Klanderman, B. 2011. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. American Journal of Respiratory and Critical Care Medicine, 183: 449-454.
17. Encode Consortium. 2007. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature, 447(7146): 799-816.
18. Fédération Internationale de Ski (FIS). 2009. FIS Anti-Doping Rules http://matrix.abss.org.br/siteABSS/web/html/ Antidoping Rules/fis-anti-doping-rules-2009.pdf
19. Fedoruk, M.N. and Rupert, J.L. 2008. Myostatin inhibition: A potential performance enhancement strategy?. Scandinavian Journal of Medicine and Science in Sports, 18: 123-131.
20. Ferrell, R.E., Conte, V., Lawrence, E.C., Roth, S.M., Hagberg, J.M. and Hurley, B.F. 1999. Frequent sequence variation in the human myostatin (GDF8) gene as a marker for analysis of muscle-related phenotypes. Genomics, 62: 203-207.
21. Gaffney, G.R. and Parisotto, R. 2007. Gene doping: A review of performance-enhancing genetics. Pediatric Clinics of North America, 54: 807-822. xii-xiii
22. Garle, M., Ocka, R., Palonek, E. and Bjorkhem, I. 1996. Increased urinary testosterone/epitestosterone ratios found in Swedish athletes in connection with a national control program: Evaluation of 28 cases. Journal of Chromatography B: Biomedical Sciences and Applications, 687: 55-59.
23. Gsur, A., Bernhofer, G., Hinteregger, S., Haidinger, G., Schatzl, G.Madersbacher, S. 2000. A polymorphism in the CYP17 gene is associated with prostate cancer risk. International Journal of Cancer, 87: 434-437.
24. Hartl, D.L. 2000. A primer of population genetics, (3rd edn.), Sunderland, MA: Sinauer Associates.
25. Holden, C. 2005. Chimera on a bike?. Science, 308(5730): 1864
26. Hou, L., Xu, J., Gao, Y.T., Rashid, A., Zheng, S.L.Sakoda, L.C. 2006. CYP17 MspA1 polymorphism and risk of biliary tract cancers and gallstones: A population-based study in Shanghai, China. International Journal of Cancer, 118: 2847-2853.
27. Jakobsson, J., Ekstrom, L., Inotsume, N., Garle, M., Lorentzon, M.Ohlsson, C. 2006. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. Journal of Clinical Endocrinology and Metabolism, 91: 687-693.
28. Jobling, M.A. and Gill, P. 2004. Encoded evidence: DNA in forensic analysis. Nature Reviews Genetics, 5: 739-751.
29. Jordan, B.D., Relkin, N.R., Ravdin, L.D., Jacobs, A.R., Bennett, A. and Gandy, S. 1997. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. Journal of the American Medical Association, 278: 136-140.
30. Karila, T., Kosunen, V., Leinonen, A., Tahtela, R. and Seppala, T. 1996. High doses of alcohol increase urinary testosterone-to-epitestosterone ratio in females. Journal of Chromatography B: Biomedical Sciences and Applications, 687: 109-116.
31. Kicman, A.T. 2010. "Biochemical and physiological aspects of endogenous androgens". In Doping in sports, Edited by: Thieme, D. and Hemmersbach, P. 25-64. Berlin: Springer. Handbook of Experimental Physiology #195
32. Kulik-Rechberger, B., Skorupski, P., Bogusiewicz, M., Miotla, P. and Rechberger, T. 2007. [Polymorphism of CYP17 gene and age of menarche]. Ginekologia Polska, 78: 929-932.
33. Kullo, I.J. and Ding, K. 2007. Mechanisms of disease: The genetic basis of coronary heart disease. Nature Clinical Practice Cardiovascular Medicine, 4: 558-569.
34. Legge, M., Fitzgerald, R. and Jones, L. 2008. An alternative consideration in drug testing in elite athletes. New Zealand Medical Journal, 121 (1278): 73-77.
35. Lippi, G. and Banfi, G. 2006. Blood transfusions in athletes: Old dogmas, new tricks. Clinical Chemistry and Laboratory Medicine, 44: 1395-1402.
36. Lippi, G., Franchini, M., Salvagno, G.L. and Guidi, G.C. 2006. Biochemistry, physiology, and complications of blood doping: Facts and speculation. Critical Reviews in Clinical Laboratory Sciences, 43: 349-391.
37. Lunn, R.M., Bell, D.A., Mohler, J.L. and Taylor, J.A. 1999. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis, 20: 1727-1731.
38. Malcovati, L., Pascutto, C. and Cazzola, M. 2003. Hematologic passport for athletes competing in endurance sports: A feasibility study. Haematologica, 88: 570-581.
39. Mallorqui, J., Segura, J., de Bolos, C., Gutierrez-Gallego, R. and Pascual, J.A. 2008. Recombinant erythropoietin found in seized blood bags from sportsmen. Haematologica, 93: 313-314.
40. McNamee, M.J., Muller, A., van Hilvoorde, I. and Holm, S. 2009. Genetic testing and sports medicine ethics. Sports Medicine, 39: 339-344.
41. McPherron, A.C., Lawler, A.M. and Lee, S.J. 1997. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature, 387 (6628): 83-90.
42. Nakazono, T., Kashimura, S., Hayashiba, Y., Hara, K. and Miyoshi, A. 2005. Successful DNA typing of urine stains using a DNA purification kit following dialfiltration. Journal of Forensic Science, 50: 860-864.
43. OMIM. 2008. Online Mendelian Inheritance in Man, OMIM, Baltimore, MD: Johns Hopkins University. http://www.ncbi. nlm.nih.gov:80/entrez/query.fcgi?db=OMIM
44. Park, J., Chen, L., Ratnashinge, L., Sellers, T.A., Tanner, J.P.Lee, J.H. 2006. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiology, Biomarkers and Prevention, 15: 1473-1478.
45. Pucsok, J.M., Gyore, I., Hollosi, I., Soos, E., Ali Ghasemi, N.R. and Frenkl, R. 2005. Urine steroid profile of judo competitors affected by acute physical exercises. Journal of Chromatographic Science, 43: 438-440.
46. Roth, S.M. 2008. Perspective on the future use of genomics in exercise prescription. Journal of Applied Physiology, 104: 1243-1245.
47. Schneider, A.J. and Rupert, J.L. 2009. Constructing winners: The science and ethics of genetically manipulating athletes. Journal of the Philosophy of Sport, 36: 182-206.
48. Schuelke, M., Wagner, K.R., Stolz, L.E., Hubner, C., Riebel, T.Komen, W. 2004. Myostatin mutation associated with gross muscle hypertrophy in a child. New England Journal of Medicine, 350: 2682-2688.
49. Schulze, J.J., Lorentzon, M., Ohlsson, C., Lundmark, J., Roh, H.K.Rane, A. 2008a. Genetic aspects of epitestosterone formation and androgen disposition: Influence of polymorphisms in CYP17 and UGT2B enzymes. Pharmacogenetics and Genomics, 18: 477-485.
50. Schulze, J.J., Lundmark, J., Garle, M., Ekstrom, L., Sottas, P.E. and Rane, A. 2008b. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests. Steroids, 74: 365-368.
51. Schulze, J.J., Lundmark, J., Garle, M., Skilving, I., Ekstrom, L. and Rane, A. 2008c. Doping test results dependent on genotype of UGT2B17, the major enzyme for testosterone glucuronidation. Journal of Clinical Endocrinology and Metabolism, 93: 2500-2506.
52. Schulze, J.J., Rane, A. and Ekstrom, L. 2009. Genetic variation in androgen disposition: Implications in clinical medicine including testosterone abuse. Expert Opinion on Drug Metabolism and Toxicology, 5: 731-744.
53. Schulze, J.J., Thorngren, J.O., Garle, M., Ekstrom, L. and Rane, A. 2011. Androgen sulfation in healthy UDP-glucuronosyl transferase 2B17 enzyme-deficient men. Journal of Clinical Endocrinology and Metabolism, 96: 3440-3447.
54. Schumacher, Y.O., Grathwohl, D., Barturen, J.M., Wollenweber, M., Heinrich, L.Schmid, A. 2000. Haemoglobin, haematocrit and red blood cell indices in elite cyclists: Are the control values for blood testing valid?. International Journal of Sports Medicine, 21: 380-385.
55. Simpson, J.L. and Elias, S. 1995. Isolating fetal cells in the maternal circulation. Human Reproduction Update, 1: 409-418.
56. Smigielski, E.M., Sirotkin, K., Ward, M. and Sherry, S.T. 2000. dbSNP: A database of single nucleotide polymorphisms. Nucleic Acids Research, 28: 352-355.
57. Sottas, P.E., Saudan, C., Schweizer, C., Baume, N., Mangin, P. and Saugy, M. 2008. From population- to subject-based limits of T/E ratio to detect testosterone abuse in elite sports. Forensic Science International, 174: 166-172.
58. Spierings, E., Hendriks, M., Absi, L., Canossi, A., Chhaya, S.Crowley, J. 2007. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genetics, 3(6): e103
59. Spriggs, M. 2004. Compulsory brain scans and genetic tests for boxers-or should boxing be banned?. Journal of Medical Ethics, 30: 515-516.
60. St. Louis, B. 2003. Sport, genetics and the "Natural Athlete": The resurgence of racial science. Body and Society, 9: 75-95.
61. Starcevic, B. and Butch, A.W. 2008. Genetic variations in UDP-glucuronosyl transferase 2B17: Implications for testosterone excretion profiling and doping control programs. Clinical Chemistry, 54: 1945-1947.
62. Starka, L., Hampl, R., Hill, M., Lapcik, O., Bilek, R. and Petrik, R. 1997. Epitestosterone in human blood and prostatic tissue. European Journal of Clinical Chemistry and Clinical Biochemistry, 35: 469-473.
63. Strahm, E., Sottas, P.E., Schweizer, C., Saugy, M., Dvorak, J. and Saudan, C. 2009. Steroid profiles of professional soccer players: An international comparative study. British Journal of Sports Medicine, 43: 1126-1130.
64. Sturm, R.A., Box, N.F. and Ramsay, M. 1998. Human pigmentation genetics: The difference is only skin deep. Bioessays, 20: 712-721.
65. Tamburrini, C.M. 2005. "Educational or genetic blueprints, what's the difference?". In Genetic technology and sport: Ethical questions, Edited by: Tamburrini, C.M. and Tännsjö, T. 82-90. London: Routledge.
66. TCPS2. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans, December 2010.
67. Videman, T., Lereim, I., Hemmingsson, P., Turner, M.S., Rousseau-Bianchi, M.P.Jenoure, P. 2000. Changes in hemoglobin values in elite cross-country skiers from 1987-1999. Scandinavian Journal of Medicine and Science in Sports, 10: 98-102.
68. Wackerhage, H., Miah, A., Harris, R.C., Montgomery, H.E. and Williams, A.G. 2009. Genetic research and testing in sport and exercise science: A review of the issues. Journal of Sports Sciences, 27: 1109-1116.
69. Wagner, K.R. 2005. Muscle regeneration through myostatin inhibition. Opinion in Rheumatology, 17: 720-724.
70. Wagner, K.R., Fleckenstein, J.L., Amato, A.A., Barohn, R.J., Bushby, K.Escolar, D.M. 2008. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Annals of Neurology, 63: 561-571.
71. Williams, A.G., Wackerhage, H., Miah, A., Harris, R.C. and Montgomery, H.E. 2009. Genetic research and testing in sport and exercise science, British Association of Sport and Exercise Sciences Position Stand. Leeds: BASES.
72. Wilson, W., III, Pardo-Manuel de Villena, F., Lyn-Cook, B.D., Chatterjee, P.K., Bell, T.A.Detwiler, D.A. 2004. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics, 84: 707-714.
73. World Anti-Doping Agency (WADA). 2004. WADA Technical Document-TD2004EAAS: Reporting and evaluation guidance for Testosterone, epitestosterone, T/E ratio and other endogenous steroids http://www.wada-ama.org/rtecontent/document/end_steroids_ aug_04.pdf